Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cymabay Therapeutics (CBAY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 131,388
  • Shares Outstanding, K 28,750
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,670 K
  • 36-Month Beta 1.99
  • Price/Sales 27.43
  • Price/Cash Flow N/A
  • Price/Book 13.07

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.16 +44.62%
on 04/27/17
4.81 -4.99%
on 05/26/17
+1.21 (+36.01%)
since 04/26/17
3-Month
2.81 +62.63%
on 02/27/17
4.81 -4.99%
on 05/26/17
+1.67 (+57.59%)
since 02/24/17
52-Week
1.15 +297.39%
on 11/09/16
4.81 -4.99%
on 05/26/17
+2.24 (+96.14%)
since 05/26/16

Most Recent Stories

More News
CymaBay Reports First Quarter 2017 Financial Results and Provides Corporate Update

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today announced financial...

CBAY : 4.57 (+9.07%)
How These Biotech Stocks are Faring? -- Cymabay Therapeutics, Benitec Biopharma, Sage Therapeutics, and Catalyst Biosciences

On Tuesday, April 25, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Eight out of nine sectors ended Tuesday's trading session in bullish...

BNTC : 2.30 (-0.43%)
CBAY : 4.57 (+9.07%)
SAGE : 66.04 (-3.10%)
CBIO : 4.27 (+7.02%)
BNIKF : 0.1392 (+3.88%)
CymaBay to Present Data from its Phase 2 Proof-of-Concept Study of Seladelpar in Patients With Primary Biliary Cholangitis at the EASL Liver Meeting 2017

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases with high unmet medical need, today announced that...

CBAY : 4.57 (+9.07%)
CymaBay Therapeutics to Present at Two Investor Conferences in April

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies for specialty and orphan diseases with high unmet medical need, today announced that management...

CBAY : 4.57 (+9.07%)
CymaBay Announces the Retirement of President and Chief Executive Officer, Harold Van Wart, Ph.D.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies for specialty and orphan diseases with high unmet medical need, today announced that Harold Van...

CBAY : 4.57 (+9.07%)
CymaBay Reports Fourth Quarter and Year End 2016 Financial Results

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today announced financial...

CBAY : 4.57 (+9.07%)
Research Reports Coverage on Biotech Stocks -- VIVUS, Ultragenyx Pharma, Cymabay Therapeutics, and Omeros

This morning, Stock-Callers.com reviews select Biotech equities, namely: VIVUS Inc. (NASDAQ: VVUS), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), Cymabay Therapeutics Inc. (NASDAQ: CBAY), and Omeros Corp....

RARE : 55.91 (-4.46%)
VVUS : 1.13 (+0.89%)
CBAY : 4.57 (+9.07%)
OMER : 15.70 (-0.88%)
CymaBay to Report Fourth Quarter And Year End 2016 Financial Results on Thursday, March 23

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today announced that it will...

CBAY : 4.57 (+9.07%)
Will Cymabay Therapeutics (CBAY) Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Cymabay Therapeutics, Inc. (CBAY)

CBAY : 4.57 (+9.07%)
CymaBay Therapeutics to Present at Two Investor Conferences in March

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today announced that management...

CBAY : 4.57 (+9.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based...

See More

Support & Resistance

2nd Resistance Point 5.15
1st Resistance Point 4.86
Last Price 4.57
1st Support Level 4.23
2nd Support Level 3.89

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.